Viridian Therapeutics, Inc.DE
Company Stats
- Market Cap
- $2.3B
- as of Sep 30, 2026
- Shares Outstanding
- 113.3M
- Free Float
- 22.9%
Income Statement
- Revenue
- $70.8M
- Operating Income
- -$363.4M
- Net Income
- -$342.6M
- EBITDA
- -$362.9M
- Revenue Growth, 3Y
- 241.9%
- FCF Margin, 3Y Avg
- -45475.2%
- FCF Margin, Worst Year
- -77096.0%
Cash Flow
- Free Cash Flow
- -$276.9M
- FCF Yield
- -11.9%
- Owner FCF Yield
- -13.8%
Returns & Capital
- SBC, 3Y Avg
- $51.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $70.8M | -$276.9M | -390.8% |
| FY2024 | $302,000 | -$232.8M | -77096.0% |
| FY2023 | $314,000 | -$185.1M | -58938.9% |
| FY2022 | $1.8M | -$94.6M | -5340.6% |
| FY2021 | $3.0M | -$54.9M | -1853.5% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 12, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
Bitmine Hits $9.8B Asset Mark; Rocket Lab to Acquire Iridium